Exagen (XGN) Competitors

$2.95 +0.01 (+0.34%)

Closing price 04:00 PM Eastern

Extended Trading

$3.00 +0.05 (+1.69%)

As of 05:54 PM Eastern

XGN vs. AIRS, LFMD, BNR, NAKA, and BDSX

Should you be buying Exagen stock or one of its competitors? The main competitors of Exagen include AirSculpt Technologies (AIRS), LifeMD (LFMD), Burning Rock Biotech (BNR), KindlyMD (NAKA), and Biodesix (BDSX). These companies are all part of the "healthcare" industry.

How does Exagen compare to AirSculpt Technologies?

AirSculpt Technologies (NASDAQ:AIRS) and Exagen (NASDAQ:XGN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, media sentiment and valuation.

AirSculpt Technologies currently has a consensus price target of $6.00, suggesting a potential upside of 55.44%. Exagen has a consensus price target of $9.38, suggesting a potential upside of 217.80%. Given Exagen's stronger consensus rating and higher possible upside, analysts clearly believe Exagen is more favorable than AirSculpt Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AirSculpt Technologies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Exagen	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

AirSculpt Technologies has a beta of 1.99, indicating that its stock price is 99% more volatile than the S&P 500. Comparatively, Exagen has a beta of 1.81, indicating that its stock price is 81% more volatile than the S&P 500.

AirSculpt Technologies has higher revenue and earnings than Exagen. AirSculpt Technologies is trading at a lower price-to-earnings ratio than Exagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AirSculpt Technologies	$151.82M	1.79	-$11.67M	-$0.19	N/A
Exagen	$66.57M	1.07	-$19.95M	-$0.92	N/A

In the previous week, AirSculpt Technologies had 4 more articles in the media than Exagen. MarketBeat recorded 5 mentions for AirSculpt Technologies and 1 mentions for Exagen. AirSculpt Technologies' average media sentiment score of 0.00 equaled Exagen'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AirSculpt Technologies	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Exagen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

AirSculpt Technologies has a net margin of -7.68% compared to Exagen's net margin of -29.97%. AirSculpt Technologies' return on equity of -5.01% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AirSculpt Technologies	-7.68%	-5.01%	-2.19%
Exagen	-29.97%	-105.03%	-30.10%

91.5% of AirSculpt Technologies shares are held by institutional investors. Comparatively, 75.3% of Exagen shares are held by institutional investors. 44.6% of AirSculpt Technologies shares are held by company insiders. Comparatively, 12.6% of Exagen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

AirSculpt Technologies beats Exagen on 11 of the 15 factors compared between the two stocks.

How does Exagen compare to LifeMD?

LifeMD (NASDAQ:LFMD) and Exagen (NASDAQ:XGN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, media sentiment and valuation.

In the previous week, LifeMD had 12 more articles in the media than Exagen. MarketBeat recorded 13 mentions for LifeMD and 1 mentions for Exagen. Exagen's average media sentiment score of 0.00 beat LifeMD's score of -0.15 indicating that Exagen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LifeMD	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Exagen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

35.5% of LifeMD shares are held by institutional investors. Comparatively, 75.3% of Exagen shares are held by institutional investors. 18.4% of LifeMD shares are held by company insiders. Comparatively, 12.6% of Exagen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

LifeMD has a net margin of 2.37% compared to Exagen's net margin of -29.97%. Exagen's return on equity of -105.03% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LifeMD	2.37%	-176.40%	-22.61%
Exagen	-29.97%	-105.03%	-30.10%

LifeMD has a beta of 2.03, indicating that its stock price is 103% more volatile than the S&P 500. Comparatively, Exagen has a beta of 1.81, indicating that its stock price is 81% more volatile than the S&P 500.

LifeMD has higher revenue and earnings than Exagen. Exagen is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LifeMD	$194.05M	1.17	$14.35M	$0.26	18.38
Exagen	$66.57M	1.07	-$19.95M	-$0.92	N/A

LifeMD currently has a consensus price target of $9.14, suggesting a potential upside of 91.27%. Exagen has a consensus price target of $9.38, suggesting a potential upside of 217.80%. Given Exagen's stronger consensus rating and higher possible upside, analysts clearly believe Exagen is more favorable than LifeMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LifeMD	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Exagen	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Summary

LifeMD beats Exagen on 10 of the 16 factors compared between the two stocks.

How does Exagen compare to Burning Rock Biotech?

Exagen (NASDAQ:XGN) and Burning Rock Biotech (NASDAQ:BNR) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

In the previous week, Exagen had 1 more articles in the media than Burning Rock Biotech. MarketBeat recorded 1 mentions for Exagen and 0 mentions for Burning Rock Biotech. Exagen's average media sentiment score of 0.00 equaled Burning Rock Biotech'saverage media sentiment score.

Company	Overall Sentiment
Exagen	Neutral
Burning Rock Biotech	Neutral

Exagen presently has a consensus target price of $9.38, suggesting a potential upside of 217.80%. Given Exagen's stronger consensus rating and higher possible upside, equities analysts clearly believe Exagen is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Exagen has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500. Comparatively, Burning Rock Biotech has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500.

Burning Rock Biotech has a net margin of -10.27% compared to Exagen's net margin of -29.97%. Burning Rock Biotech's return on equity of -9.98% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-29.97%	-105.03%	-30.10%
Burning Rock Biotech	-10.27%	-9.98%	-6.69%

75.3% of Exagen shares are owned by institutional investors. Comparatively, 30.0% of Burning Rock Biotech shares are owned by institutional investors. 12.6% of Exagen shares are owned by insiders. Comparatively, 30.3% of Burning Rock Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Burning Rock Biotech has higher revenue and earnings than Exagen. Burning Rock Biotech is trading at a lower price-to-earnings ratio than Exagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$66.57M	1.07	-$19.95M	-$0.92	N/A
Burning Rock Biotech	$539.57M	0.33	-$7.92M	-$0.79	N/A

Summary

Exagen beats Burning Rock Biotech on 8 of the 15 factors compared between the two stocks.

How does Exagen compare to KindlyMD?

Exagen (NASDAQ:XGN) and KindlyMD (NASDAQ:NAKA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.

Exagen has higher revenue and earnings than KindlyMD. Exagen is trading at a lower price-to-earnings ratio than KindlyMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$66.57M	1.07	-$19.95M	-$0.92	N/A
KindlyMD	$1.82M	67.14	-$52.23M	-$0.87	N/A

Exagen has a beta of 1.81, indicating that its stock price is 81% more volatile than the S&P 500. Comparatively, KindlyMD has a beta of 17.12, indicating that its stock price is 1,612% more volatile than the S&P 500.

In the previous week, Exagen and Exagen both had 1 articles in the media. KindlyMD's average media sentiment score of 1.02 beat Exagen's score of 0.00 indicating that KindlyMD is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exagen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
KindlyMD	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Exagen presently has a consensus target price of $9.38, suggesting a potential upside of 217.80%. KindlyMD has a consensus target price of $0.75, suggesting a potential upside of 323.49%. Given KindlyMD's higher possible upside, analysts plainly believe KindlyMD is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
KindlyMD	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Exagen has a net margin of -29.97% compared to KindlyMD's net margin of -2,866.57%. KindlyMD's return on equity of -16.11% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-29.97%	-105.03%	-30.10%
KindlyMD	-2,866.57%	-16.11%	-11.25%

75.3% of Exagen shares are owned by institutional investors. 12.6% of Exagen shares are owned by insiders. Comparatively, 24.5% of KindlyMD shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

KindlyMD beats Exagen on 9 of the 15 factors compared between the two stocks.

How does Exagen compare to Biodesix?

Biodesix (NASDAQ:BDSX) and Exagen (NASDAQ:XGN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, earnings, institutional ownership and profitability.

In the previous week, Biodesix had 8 more articles in the media than Exagen. MarketBeat recorded 9 mentions for Biodesix and 1 mentions for Exagen. Biodesix's average media sentiment score of 0.33 beat Exagen's score of 0.00 indicating that Biodesix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biodesix	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
Exagen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Biodesix has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500. Comparatively, Exagen has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500.

21.0% of Biodesix shares are held by institutional investors. Comparatively, 75.3% of Exagen shares are held by institutional investors. 23.2% of Biodesix shares are held by company insiders. Comparatively, 12.6% of Exagen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Exagen has lower revenue, but higher earnings than Biodesix. Biodesix is trading at a lower price-to-earnings ratio than Exagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biodesix	$96.10M	1.61	-$35.26M	-$4.06	N/A
Exagen	$66.57M	1.07	-$19.95M	-$0.92	N/A

Exagen has a net margin of -29.97% compared to Biodesix's net margin of -33.26%. Exagen's return on equity of -105.03% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biodesix	-33.26%	-2,101.40%	-35.65%
Exagen	-29.97%	-105.03%	-30.10%

Biodesix currently has a consensus target price of $33.00, indicating a potential upside of 115.40%. Exagen has a consensus target price of $9.38, indicating a potential upside of 217.80%. Given Exagen's stronger consensus rating and higher probable upside, analysts plainly believe Exagen is more favorable than Biodesix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biodesix	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Exagen	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Summary

Exagen beats Biodesix on 11 of the 16 factors compared between the two stocks.

Get Exagen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XGN vs. The Competition

Export

Metric	Exagen	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$71.21M	$7.87B	$6.18B	$12.29B
Dividend Yield	N/A	2.45%	2.78%	5.24%
P/E Ratio	-3.21	124.38	28.73	27.27
Price / Sales	1.07	7.67	507.29	64.11
Price / Cash	N/A	17.04	43.30	53.97
Price / Book	3.83	3.50	10.00	6.83
Net Income	-$19.95M	$223.69M	$3.54B	$332.87M
7 Day Performance	N/A	N/A	N/A	0.09%
1 Month Performance	-4.22%	8.12%	4.66%	7.36%
1 Year Performance	-52.11%	2.23%	40.41%	41.09%

Exagen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XGN Exagen	3.6561 of 5 stars	$2.95 +0.3%	$9.38 +217.8%	-57.0%	$71.21M	$66.57M	N/A	220	Upcoming Earnings
AIRS AirSculpt Technologies	2.1421 of 5 stars	$3.52 +2.3%	$6.00 +70.5%	+35.2%	$242.68M	$151.82M	N/A	240	News Coverage Gap Up
LFMD LifeMD	3.5653 of 5 stars	$5.13 +0.8%	$9.14 +78.2%	-44.1%	$242.28M	$194.05M	19.73	230	Earnings Report Analyst Upgrade
BNR Burning Rock Biotech	1.1431 of 5 stars	$17.02 -1.0%	N/A	+614.7%	$184.99M	$77.16M	N/A	1,390
NAKA KindlyMD	4.1246 of 5 stars	$0.20 +2.1%	$0.75 +284.6%	N/A	$131.79M	$1.82M	N/A	N/A	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XGN) was last updated on 5/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Exagen (XGN) Competitors

XGN vs. AIRS, LFMD, BNR, NAKA, and BDSX

How does Exagen compare to AirSculpt Technologies?

Summary

How does Exagen compare to LifeMD?

Summary

How does Exagen compare to Burning Rock Biotech?

Summary

How does Exagen compare to KindlyMD?

Summary

How does Exagen compare to Biodesix?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XGN vs. The Competition

Exagen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Exagen (XGN) Competitors

XGN vs. AIRS, LFMD, BNR, NAKA, and BDSX

How does Exagen compare to AirSculpt Technologies?

Do analysts prefer AIRS or XGN?

Which has more risk & volatility, AIRS or XGN?

Which has better earnings & valuation, AIRS or XGN?

Does the media favor AIRS or XGN?

Is AIRS or XGN more profitable?

Do insiders and institutionals have more ownership in AIRS or XGN?

Summary

How does Exagen compare to LifeMD?

Does the media favor LFMD or XGN?

Do insiders and institutionals have more ownership in LFMD or XGN?

Is LFMD or XGN more profitable?

Which has more risk & volatility, LFMD or XGN?

Which has better earnings & valuation, LFMD or XGN?

Do analysts prefer LFMD or XGN?

Summary

How does Exagen compare to Burning Rock Biotech?

Does the media prefer XGN or BNR?

Do analysts recommend XGN or BNR?

Which has more volatility and risk, XGN or BNR?

Is XGN or BNR more profitable?

Do institutionals and insiders hold more shares of XGN or BNR?

Which has higher valuation and earnings, XGN or BNR?

Summary

How does Exagen compare to KindlyMD?

Which has stronger valuation & earnings, XGN or NAKA?

Which has more risk and volatility, XGN or NAKA?

Does the media prefer XGN or NAKA?

Do analysts prefer XGN or NAKA?

Is XGN or NAKA more profitable?

Do insiders & institutionals hold more shares of XGN or NAKA?

Summary

How does Exagen compare to Biodesix?

Does the media favor BDSX or XGN?

Which has more volatility and risk, BDSX or XGN?

Do institutionals & insiders hold more shares of BDSX or XGN?

Which has preferable earnings and valuation, BDSX or XGN?

Is BDSX or XGN more profitable?

Do analysts rate BDSX or XGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XGN vs. The Competition

Exagen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools